Proteomics phenotype

Chertov, A., Fenselau, C. (2004). Proteomic phenotyping metastatic and invasive breast cancer. Cancer Lett. 210, 245-253. 

RT-PCR, proteomics, phenotypic assaying using antibodies, and many more [75-77]. 

The statement that genomic analysis is sufficient for disease-related research has long been proven wrong. In contrast, the translation products, the proteins, are the exe-cuters of cell functions and are of major interest. The example of the caterpillar and the butterfly that have the same genotype, but a quite different phenotype, is often used to exemplify the need for proteomics. However, the study of proteins is complicated by a number of facts ... 

Siest, G., Marteau, J.B., Maumus, S., et al. (2005) Pharmacogenomics and cardiovascular drugs need for integrated biological system with phenotypes and proteomic markers. Eur. J. Pharmacol. 527, 1-22. 

Proteomics includes a variety of technologies that include differential protein display on gels, protein chips, quantitation of protein amoimts, analysis of post-translational modifications, characterization of protein complexes and networks and bioinformatics. All this information in combination with genome and phenotype studies will ultimately yield a comprehensive picture of a cellular or tissue proteome (Wasinger and Corthals 2002). 

Fig. 1. Work flow and purpose of cancer profeomics. Profeomic profiles of fumor fissues are infegrated wifh clinico-pafhological data to identify the proteomic aberrations governing cancer phenotypes. The goals of cancer proteomics are understanding of the molecular mechanisms of cancer diversity and developing applications of potential clinical benefit.

---